Panion & BF Biotech Inc.   Report issue

Contributed to NME For profit Phase 3 Phase 4
Founded: Taipei Taiwan (1976)

Organization Overview

First Clinical Trial
2010
NCT01503736
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Panion & BF Biotech Inc. | Shandong Weigao Panion Pharmaceutical Co. Ltd.

Active Ingredients

Drugs in Phase 4 Trials (1)

ferric citrate (AURYXIA) (4 trials)

Drugs in Phase 3 Trials (1)

sevelamer (renagel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Hyperphosphatemia (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Metabolic Diseases (Phase 4)

Phosphorus Metabolism Disorders (Phase 4)

Renal Insufficiency (Phase 4)

Renal Insufficiency, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 2